https://epignostix.com/2024/07/16/heidelberg-epignostix-appoints-helge-lubenow-as-ceo/2026-08-28T00:35:42+02:00https://epignostix.com/2024/07/02/dkfz-spin-off-epignostix-raises-e4-3m-seed-round-to-commercialize-diagnostic-tumor-classifier/2026-08-28T00:25:09+02:00https://epignostix.com/2025/01/22/epignostix-launches-cns-and-sarcoma-diagnostic-tumor-classifier-applications/2026-08-30T21:53:46+02:00https://epignostix.com/2025/05/06/epignostix-announces-cms-release-of-a-preliminary-gapfill-price-for-their-proprietary-cpt-code-for-the-epignostix-cns-tumor-methylation-classifier-test/2026-08-28T00:38:12+02:00https://epignostix.com/2025/07/08/epignostix-launches-advanced-dna-methylation-based-sarcoma-classifier/2026-08-28T00:38:12+02:00https://epignostix.com/2026/06/01/heidelberg-epignostix-appoints-co-founder-prof-dr-dr-med-felix-sahm-as-chief-medical-advisor/2026-08-28T00:32:05+02:00https://epignostix.com/2026/09/01/heidelberg-epignostix-announces-strategic-partnership-to-bring-epigenetic-tumour-classifiers-to-nhs-genomics-services/2026-09-01T10:04:50+02:00